{"filing":{"accession_number":"0001193125-26-389844","cik":"0001789972","ticker":"CGEM","company_name":"Cullinan Therapeutics, Inc.","form":"8-K","filing_date":"2026-09-14","report_date":"2026-09-13","primary_document":"cgem-20260913.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1789972/000119312526389844/cgem-20260913.htm"},"events":[{"id":33113,"run_id":30438,"accession_number":"0001193125-26-389844","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Cullinan Therapeutics announced positive Phase 3 clinical trial results for zipalertinib (CLN-081/TAS6417) in the REZILIENT3 trial, demonstrating a statistically significant 6-month median progression-free survival benefit (14.5 vs. 8.5 months; HR 0.50; P=0.00015) in first-line EGFR exon 20 insertion mutation NSCLC. This material clinical milestone supports potential regulatory advancement and commercialization of a key pipeline asset.","company_name":"Cullinan Therapeutics, Inc.","ticker":"CGEM","filing_date":"2026-09-14","form":"8-K","submitted_at":null,"items":[{"id":36463,"accession_number":"0001193125-26-389844","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This disclosure announces positive Phase 3 clinical trial results for zipalertinib (CLN-081/TAS6417) in the REZILIENT3 trial, demonstrating a statistically significant 6-month median PFS benefit in first-line EGFR exon 20 insertion mutation NSCLC. The event is a material clinical milestone for a biopharmaceutical company's pipeline advancement, but does not fit the specific earnings_release category (which typically applies to financial results) nor any other defined event type. As a material operational/clinical development milestone that would affect investor assessment of the company's product prospects, it is best classified as operational_other.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-14T11:30:42.026376+00:00","company_name":"","ticker":null,"filing_date":""},{"id":36464,"accession_number":"0001193125-26-389844","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces positive Phase 3 clinical trial results for zipalertinib (CLN-081/TAS6417) in the REZILIENT3 trial, demonstrating a statistically significant 6-month median PFS benefit (14.5 vs. 8.5 months; HR 0.50; P=0.00015) in first-line EGFR exon 20 insertion NSCLC. This is a material operational/clinical milestone for a biopharmaceutical company's development pipeline, but does not fit the specific categories of earnings release, exec changes, M\u0026A, impairment, or other defined event types. The results support potential regulatory advancement and commercialization of a key pipeline asset.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-14T11:30:42.026376+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":36463,"accession_number":"0001193125-26-389844","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This disclosure announces positive Phase 3 clinical trial results for zipalertinib (CLN-081/TAS6417) in the REZILIENT3 trial, demonstrating a statistically significant 6-month median PFS benefit in first-line EGFR exon 20 insertion mutation NSCLC. The event is a material clinical milestone for a biopharmaceutical company's pipeline advancement, but does not fit the specific earnings_release category (which typically applies to financial results) nor any other defined event type. As a material operational/clinical development milestone that would affect investor assessment of the company's product prospects, it is best classified as operational_other.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-14T11:30:42.026376+00:00","company_name":"Cullinan Therapeutics, Inc.","ticker":"CGEM","filing_date":"2026-09-14"},{"id":36464,"accession_number":"0001193125-26-389844","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces positive Phase 3 clinical trial results for zipalertinib (CLN-081/TAS6417) in the REZILIENT3 trial, demonstrating a statistically significant 6-month median PFS benefit (14.5 vs. 8.5 months; HR 0.50; P=0.00015) in first-line EGFR exon 20 insertion NSCLC. This is a material operational/clinical milestone for a biopharmaceutical company's development pipeline, but does not fit the specific categories of earnings release, exec changes, M\u0026A, impairment, or other defined event types. The results support potential regulatory advancement and commercialization of a key pipeline asset.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-14T11:30:42.026376+00:00","company_name":"Cullinan Therapeutics, Inc.","ticker":"CGEM","filing_date":"2026-09-14"}]}